

# Roberto Labianca

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1028899/roberto-labianca-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

236 papers	21,383 citations	68 h-index	144 g-index
251 ext. papers	24,053 ext. citations	5.1 avg, IF	5.94 L-index

#	Paper	IF	Citations
236	Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. <i>European Journal of Cancer</i> , <b>2021</b> , 148, 190-201	7.5	0
235	Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence. <i>TH Open</i> , <b>2021</b> , 5, e56-e65	2.7	5
234	Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 631-641	2.2	17
233	Thrombin generation predicts early recurrence in breast cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 2220-2231	15.4	6
232	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. <i>European Journal of Cancer</i> , <b>2020</b> , 130, 63-71	7.5	7
231	Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis. <i>Oncologist</i> , <b>2020</b> , 25, e928-e935	5.7	5
230	Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. <i>Lancet Oncology</i> , <b>2020</b> , 21, 1620-1629	21.7	55
229	Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer. <i>Haematologica</i> , <b>2020</b> , 105, 1704-1711	6.6	8
228	Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. <i>Scientific Reports</i> , <b>2019</b> , 9, 11527	4.9	9
227	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. <i>Lancet Oncology</i> , <b>2018</b> , 19, e151-e160	21.7	31
226	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1177-1188	59.2	429
225	FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1478-1485	2.2	41
224	Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review. <i>European Journal of Cancer</i> , <b>2017</b> , 81, 174-182	7.5	9
223	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1182-9	2.2	22
222	A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma. <i>Annals of Oncology</i> , <b>2016</b> , 27, 274-80	10.3	79
221	Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study. <i>Thrombosis Research</i> , <b>2016</b> , 140 Suppl 1, S55-9	8.2	19
220	Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. <i>Journal of Geriatric Oncology</i> , <b>2016</b> , 7, 422-429	3.6	6

219	Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population. <i>Annals of Oncology</i> , <b>2015</b> , 26, 950-958	10.3	8
218	Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial. <i>Oncology</i> , <b>2015</b> , 88, 273-80	3.6	23
217	Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. <i>Annals of Oncology</i> , <b>2015</b> , 26, 2079-84	10.3	35
216	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. <i>Modern Pathology</i> , <b>2015</b> , 28, 1481-91	9.8	144
215	Addressing the challenges of pancreatic cancer: future directions for improving outcomes. <i>Pancreatology</i> , <b>2015</b> , 15, 8-18	3.8	277
214	MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma. <i>Liver International</i> , <b>2015</b> , 35, 1077-86	7.9	56
213	Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). <i>Scientific Reports</i> , <b>2015</b> , 5, 16331	4.9	9
212	The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. <i>Oncotarget</i> , <b>2015</b> , 6, 35087-94	3.3	36
211	FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study. <i>Clinical Colorectal Cancer</i> , <b>2015</b> , 14, 162-9	3.8	7
210	Time required to start multicentre clinical trials within the Italian Medicine Agency programme of support for independent research. <i>Journal of Medical Ethics</i> , <b>2015</b> , 41, 799-803	2.5	4
209	Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). <i>European Journal of Cancer</i> , <b>2014</b> , 50, 2983-93	7.5	45
208	A prospective study on survival in cancer patients with and without venous thromboembolism. <i>Internal and Emergency Medicine</i> , <b>2014</b> , 9, 559-67	3.7	23
207	Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. <i>Scientific Reports</i> , <b>2014</b> , 4, 6828	4.9	29
206	Tivantinib: critical review with a focus on hepatocellular carcinoma. <i>Expert Opinion on Investigational Drugs</i> , <b>2014</b> , 23, 1563-74	5.9	15
205	Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1373-1378	10.3	61
204	Adjuvant low-dose interleukin-2 (IL-2) plus interferon- $\gamma$ (IFN- $\gamma$ ) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC). <i>Journal of Immunotherapy</i> , <b>2014</b> , 37, 440-7	5	46
203	ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	48
202	Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 182-6	3.3	34

201	"Green Oncology": the Italian medical oncologists' challenge to reduce the ecological impact of their clinical activity. <i>Tumori</i> , <b>2014</b> , 100, e94-7	1.7	2
200	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. <i>Lancet Oncology</i> , <b>2013</b> , 14, 981-8	21.7	402
199	Hepatitis B in immunosuppressed cancer patients: pathogenesis, incidence and prophylaxis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2013</b> , 87, 12-27	7	15
198	The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. <i>Current Colorectal Cancer Reports</i> , <b>2013</b> , 9, 261-269	1	82
197	Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. <i>Cancer</i> , <b>2013</b> , 119, 1528-36	6.4	104
196	Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY). <i>European Urology</i> , <b>2013</b> , 63, 254-61	10.2	24
195	Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2013</b> , 24 Suppl 6, vi64-72	10.3	580
194	Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. <i>Annals of Oncology</i> , <b>2013</b> , 24, 406-411	10.3	91
193	Appropriateness and right price: an inseparable binomial to improve care and reduce cost. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2223	2.2	1
192	A randomized phase II non-comparative study of pemetrexed-carboplatin and gemcitabine-vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients. <i>International Journal of Oncology</i> , <b>2013</b> , 42, 1778-85	4.4	10
191	The MaiSON Project (Italy). Developing integration strategies for oncology organizations/associations through a participatory approach. <i>Tumori</i> , <b>2013</b> , 99, 122-4	1.7	
190	Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI-Italian questionnaire for intense episodic pain. <i>Journal of Pain and Symptom Management</i> , <b>2012</b> , 43, 833-41	4.8	51
189	Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4501-7	2.2	36
188	ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. <i>Annals of Oncology</i> , <b>2012</b> , 23, 2479-2516	10.3	984
187	Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. <i>Journal of the National Cancer Institute</i> , <b>2012</b> , 104, 1635-46	9.7	180
186	Barriers to pain management: focus on opioid therapy. <i>Clinical Drug Investigation</i> , <b>2012</b> , 32 Suppl 1, 11-9	3.2	38
185	The appropriate treatment of chronic pain. <i>Clinical Drug Investigation</i> , <b>2012</b> , 32 Suppl 1, 21-33	3.2	52
184	Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain. <i>Clinical Drug Investigation</i> , <b>2012</b> , 32 Suppl 1, 53-63	3.2	115

183	The management of chronic pain in important patient subgroups. <i>Clinical Drug Investigation</i> , <b>2012</b> , 32 Suppl 1, 35-44	3.2	25
182	A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. <i>Internal and Emergency Medicine</i> , <b>2012</b> , 7, 291-2	3.7	23 <sup>1</sup>
181	FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2012</b> , 69, 1641-5	3.5	68
180	Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2334-9	2.2	24
179	Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies. <i>British Journal of Cancer</i> , <b>2012</b> , 107, 612-6	8.7	4
178	Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). <i>British Journal of Cancer</i> , <b>2012</b> , 106, 658-65	8.7	14
177	Tackling off-label use of anticancer drugs. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2800; author reply 2801	2.2	3
176	Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. <i>British Journal of Cancer</i> , <b>2011</b> , 104, 1786-90	8.7	55
175	Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 68, 37-43	3.5	14
174	Chemotherapy-associated thrombotic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. <i>Journal of Translational Medicine</i> , <b>2011</b> , 9, 179	8.5	75
173	Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations. <i>Clinical Lung Cancer</i> , <b>2011</b> , 12, 138-41	4.9	14
172	DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. <i>Journal of the National Cancer Institute</i> , <b>2011</b> , 103, 863-75	9.7	39 <sup>0</sup>
171	Association of socioeconomic status with Breslow thickness and disease-free and overall survival in stage I-II primary cutaneous melanoma. <i>Mayo Clinic Proceedings</i> , <b>2011</b> , 86, 113-9	6.4	27
170	Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. <i>Annals of Oncology</i> , <b>2011</b> , 22, 1236-1242	10.3	85
169	Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, e819-22	2.2	56
168	Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1645-51	2.2	23 <sup>7</sup>
167	Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. <i>Annals of Oncology</i> , <b>2010</b> , 21, 871-876	10.3	64
166	Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study. <i>Nephron Clinical Practice</i> , <b>2010</b> , 115, c154-60		68

165	Video meliora proboque sed deteriora sequor: the case of thromboprophylaxis in hospitalized cancer patients. <i>Annals of Oncology</i> , <b>2010</b> , 21, 911-3	10.3	2
164	Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. <i>Annals of Oncology</i> , <b>2010</b> , 21 Suppl 5, v70-7	10.3	226
163	Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3219-26	2.2	1063
162	Cholangiocarcinoma: A position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiotherapy (AIRO). <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 231-8	3.3	25
161	Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 466-74	2.2	889
160	Venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and management. <i>Thrombosis Research</i> , <b>2010</b> , 125 Suppl 2, S117-9	8.2	31
159	Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2010</b> , 59, 553-61	7.4	19
158	Colon cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2010</b> , 74, 106-33	7	172
157	Off-Label Prescription of Antineoplastic Drugs: An Italian Prospective, Observational, Multicenter Survey. <i>Tumori</i> , <b>2009</b> , 95, 647-651	1.7	13
156	Prospective, multicenter, randomized trial of a new organizational modality for providing information and support to cancer patients. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1794-9	2.2	12
155	The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. <i>Annals of Oncology</i> , <b>2009</b> , 20 Suppl 7, vii1-vii6	10.3	84
154	Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. <i>Annals of Oncology</i> , <b>2009</b> , 20, 1062-7	10.3	15
153	Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 872-7	2.2	400
152	Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3117-25	2.2	354
151	Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. <i>BMC Cancer</i> , <b>2009</b> , 9, 303	4.8	60
150	Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 64, 769-75	3.5	75
149	Cholangiocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , <b>2009</b> , 69, 259-70	7	121
148	Rectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2009</b> , 70, 160-82	7	12



147	Gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2009</b> , 71, 127-64	7	316
146	Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 65-73	7.5	47
145	Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 2537-45	7.5	72
144	An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy. <i>Lung Cancer</i> , <b>2009</b> , 64, 199-206	5.9	19
143	Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. <i>Lancet Oncology, The</i> , <b>2009</b> , 10, 943-9	21.7	443
142	Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: results from the Cancer Pain Outcome Research (CPOR) Study Group. <i>Clinical Journal of Pain</i> , <b>2009</b> , 25, 671-82	3.5	7
141	A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. <i>British Journal of Cancer</i> , <b>2008</b> , 98, 71-6	8.7	36
140	Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. <i>BMC Cancer</i> , <b>2008</b> , 8, 82	4.8	315
139	Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. <i>European Urology</i> , <b>2008</b> , 54, 1089-94	10.2	106
138	Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting. <i>Clinical Drug Investigation</i> , <b>2008</b> , 28, 645-55	3.2	22
137	Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). <i>European Journal of Cancer</i> , <b>2008</b> , 44, 2204-11	7.5	34
136	Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. <i>Lancet Oncology, The</i> , <b>2008</b> , 9, 39-44	21.7	114
135	The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. <i>Annals of Oncology</i> , <b>2008</b> , 19 Suppl 6, vi1-8	10.3	49
134	Impact of recent legislative bills regarding clinical research on Italian ethics committee activity. <i>Journal of Medical Ethics</i> , <b>2008</b> , 34, 747-50	2.5	10
133	Venous thromboembolism and pancreatic cancer: incidence, pathogenesis and clinical implications. <i>Onkologie</i> , <b>2008</b> , 31, 129-35		3
132	Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4906-11	2.2	423
131	Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1619-25	2.2	131
130	Perioperative or postoperative therapy for resectable gastric cancer??. <i>Annals of Oncology</i> , <b>2008</b> , 19 Suppl 5, v99-102	10.3	4

129	Axillary recurrence in sentinel lymph node-negative breast cancer patients. <i>Annals of Oncology</i> , <b>2008</b> , 19, 1842-6	10.3	16
128	Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 388-98	9.7	105
127	Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. <i>Journal of Thoracic Oncology</i> , <b>2008</b> , 3, 764-71	8.9	41
126	Prevalence and treatment of cancer pain in Italian oncological wards centres: a cross-sectional survey. <i>Supportive Care in Cancer</i> , <b>2008</b> , 16, 1203-11	3.9	28
125	Reversible palpebral ptosis following oxaliplatin infusion. <i>Digestive and Liver Disease</i> , <b>2007</b> , 39, 1041	3.3	4
124	Comprehensive Geriatric Assessment in Elderly Cancer Patients: An Experience in an Outpatient Population. <i>Tumori</i> , <b>2007</b> , 93, 23-25	1.7	13
123	The role of adjuvant chemotherapy in colon cancer. <i>Surgical Oncology</i> , <b>2007</b> , 16 Suppl 1, S93-6	2.5	10
122	Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial?. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4320-1; author reply 4321-2	2.2	3
121	Neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2007</b> , 7, 887-97	3.5	9
120	What is the real benefit of adjuvant chemotherapy in the Adjuvant Navelbine International Trialist Association trial?. <i>Annals of Oncology</i> , <b>2007</b> , 18, 404	10.3	
119	Response: Re: Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients with 5-Fluorouracil, Leucovorin, Cisplatin, and Epi-doxorubicin in a Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , <b>2007</b> , 99, 1346-1347	9.7	1
118	Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. <i>Journal of the National Cancer Institute</i> , <b>2007</b> , 99, 998-1003	9.7	240
117	Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. <i>Annals of Oncology</i> , <b>2007</b> , 18, 1660-5	10.3	92
116	Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. <i>Annals of Oncology</i> , <b>2007</b> , 18, 1652-9	10.3	91
115	Agreement between oncology guidelines and clinical practice in Italy: the 'right' program. A project of the Italian Association of Medical Oncology (AIOM). <i>Annals of Oncology</i> , <b>2007</b> , 18 Suppl 6, vi179-84	10.3	10
114	Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3930-5	2.2	103
113	Breast cancer follow-up: just a burden, or much more?. <i>Annals of Oncology</i> , <b>2007</b> , 18, 1431-2	10.3	2
112	Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. <i>Journal of the National Cancer Institute</i> , <b>2007</b> , 99, 601-7	9.7	88



111	End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4569-74	2.2	183
110	Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 326-31	2.2	414
109	Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study. <i>World Journal of Gastroenterology</i> , <b>2007</b> , 13, 6553	5.6	4
108	Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). <i>Critical Reviews in Oncology/Hematology</i> , <b>2006</b> , 59, 194-204	7	102
107	Targeted therapies for patients with advanced colorectal cancer: focus on cetuximab. <i>Targeted Oncology</i> , <b>2006</b> , 1, 2-12	5	2
106	Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study. <i>Oncology</i> , <b>2006</b> , 71, 374-81	3.6	14
105	Buprenorphine-induced acute respiratory depression during ifosfamide-based chemotherapy. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1466-7	10.3	3
104	Challenges in the treatment of gastrointestinal tumours. <i>Annals of Oncology</i> , <b>2006</b> , 17 Suppl 5, v137-41	10.3	2
103	Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 4668-9; author reply 4669	2.2	
102	Introduction. Gemcitabine: ten years of clinical experience. <i>Annals of Oncology</i> , <b>2006</b> , 17 Suppl 5, v5-6	10.3	5
101	New strategies in colon cancer adjuvant therapy. <i>Annals of Oncology</i> , <b>2006</b> , 17 Suppl 7, vii51-4	10.3	5
100	Targeted therapy in colorectal cancer: do we know enough?. <i>Digestive and Liver Disease</i> , <b>2006</b> , 38, 71-7	3.3	5
99	Pain in cancer. An outcome research project to evaluate the epidemiology, the quality and the effects of pain treatment in cancer patients. <i>Health and Quality of Life Outcomes</i> , <b>2006</b> , 4, 7	3	15
98	Capecitabine and Mitomycin c May be an Effective Treatment Option for Third-line Chemotherapy in Advanced Colorectal Cancer. <i>Tumori</i> , <b>2006</b> , 92, 384-388	1.7	12
97	Oncologists' opinions about research ethics committees in Italy: an update, 2004. <i>European Journal of Cancer Prevention</i> , <b>2006</b> , 15, 91-4	2	3
96	Edmonton symptom assessment scale: Italian validation in two palliative care settings. <i>Supportive Care in Cancer</i> , <b>2006</b> , 14, 30-7	3.9	148
95	Optimizing use of opiates in the management of cancer pain. <i>Therapeutics and Clinical Risk Management</i> , <b>2006</b> , 2, 447-53	2.9	16
94	Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 8664-70	2.2	509

93	Gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2005</b> , 54, 209-41	7	65
92	Midazolam for long-term treatment of intractable hiccup. <i>Journal of Pain and Symptom Management</i> , <b>2005</b> , 29, 221-3	4.8	16
91	A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma. <i>Cancer</i> , <b>2005</b> , 103, 772-9	6.4	8
90	Colorectal cancer: screening. <i>Annals of Oncology</i> , <b>2005</b> , 16 Suppl 2, ii127-32	10.3	21
89	The development of clinical research in CRC. <i>Annals of Oncology</i> , <b>2005</b> , 16 Suppl 4, iv37-43	10.3	13
88	The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. <i>Oncology</i> , <b>2005</b> , 68, 212-6	3.6	3
87	Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 3509-16	2.2	780
86	Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 1797-806	2.2	769
85	Insurance for independent cancer trials. <i>Annals of Oncology</i> , <b>2004</b> , 15, 1722-3	10.3	2
84	High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>British Journal of Cancer</i> , <b>2004</b> , 90, 1521-5	8.7	53
83	Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 750-8	9.7	21
82	Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil. <i>British Journal of Cancer</i> , <b>2004</b> , 91, 1428-33	8.7	1
81	Adjuvant treatment of colorectal cancer. <i>Surgical Oncology</i> , <b>2004</b> , 13, 63-73	2.5	14
80	Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions. <i>Supportive Care in Cancer</i> , <b>2004</b> , 12, 446-53	3.9	29
79	Colon cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2004</b> , 51, 145-70	7	27
78	Rectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2004</b> , 51, 121-43	7	8
77	The role of uracil-tegafur (UFT) in elderly patients with colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2004</b> , 52, 73-80	7	3
76	Colorectal cancer in 2003: state of the art and new developments. <i>European Journal of Cancer, Supplement</i> , <b>2004</b> , 2, 1-2	1.6	

75	Elderly colorectal cancer patients are under treated. <i>European Journal of Cancer, Supplement</i> , <b>2004</b> , 2, 8-13	1.6	3
74	Population-based sentinel lymph node biopsy in early invasive breast cancer. <i>European Journal of Surgical Oncology</i> , <b>2004</b> , 30, 618-23	3.6	2
73	Adjuvant therapy for stage II colon cancer: an elephant in the living room?. <i>Annals of Oncology</i> , <b>2004</b> , 15, 1310-8	10.3	50
72	A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. <i>British Journal of Cancer</i> , <b>2003</b> , 89, 1428-32	8.7	17
71	Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. <i>Annals of Oncology</i> , <b>2003</b> , 14, 1570-7	10.3	352
70	Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy. <i>Annals of Oncology</i> , <b>2003</b> , 14, 843-8	10.3	23
69	Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>Annals of Oncology</i> , <b>2003</b> , 14, 205-8	10.3	24
68	Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas?. <i>Oncology</i> , <b>2003</b> , 64, 186-8	3.6	14
67	Pain and its treatment in hospitalized patients with metastatic cancer. <i>Supportive Care in Cancer</i> , <b>2003</b> , 11, 587-92	3.9	33
66	Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial. <i>Journal of Translational Medicine</i> , <b>2003</b> , 1, 13	8.5	8
65	Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. <i>European Journal of Cancer</i> , <b>2003</b> , 39, 1577-85	7.5	48
64	Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. <i>European Journal of Cancer</i> , <b>2003</b> , 39, 1948-56	7.5	79
63	Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 1600-7	2.2	99
62	MisuraProject: A Retrospective Survey on the Use of 5fluorouracil in the Treatment of Colorectal Cancer in 24 Italian Clinical Centers. <i>Tumori</i> , <b>2002</b> , 88, 104-109	1.7	1
61	Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: a low cost effective regimen. <i>British Journal of Cancer</i> , <b>2002</b> , 86, 213-7	8.7	13
60	Cisplatin, Dacarbazine With or Without Subcutaneous Interleukin-2, and Interferon Alfa-2b in Advanced Melanoma Outpatients: Results From an Italian Multicenter Phase III Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 1600-1607	2.2	60
59	Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 3478-83	2.2	265
58	Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). <i>Annals of Oncology</i> , <b>2002</b> , 13, 716-20	10.3	41

57	Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. <i>Annals of Oncology</i> , <b>2002</b> , 13, 1438-46	10.3	169
56	Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). <i>European Journal of Cancer</i> , <b>2002</b> , 38, 1429-36	7.5	47
55	Individual Tailored Chemotherapy. <i>Tumori</i> , <b>2002</b> , 1, S25-S27	1.7	
54	Is There an Advantage for Oral Therapy in Elderly? Uft. <i>Tumori</i> , <b>2002</b> , 88, S71-S72	1.7	
53	Medical Treatment of Colorectal Cancer in Elderly (>70 Years): Giscad Experience and Future Perspectives. <i>Tumori</i> , <b>2002</b> , 88, S109-S112	1.7	2
52	Treatment of classical Kaposi's sarcoma with gemcitabine. <i>Dermatology</i> , <b>2001</b> , 202, 119-22	4.4	31
51	A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. <i>British Journal of Cancer</i> , <b>2001</b> , 84, 470-4	8.7	34
50	A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 1091-7	59.2	784
49	New drugs and combinations in the palliative treatment of colon and rectal cancer. <i>European Journal of Surgical Oncology</i> , <b>2001</b> , 27, 595-600	3.6	11
48	A multinational study to measure the value that patients with cancer place on improved emesis control following cisplatin chemotherapy. <i>Pharmacoeconomics</i> , <b>2001</b> , 19, 955-67	4.4	15
47	Pre-operative endocrine therapy for postmenopausal women: when and why?. <i>Annals of Oncology</i> , <b>2001</b> , 12, 1505-6	10.3	3
46	Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. <i>Annals of Oncology</i> , <b>2001</b> , 12, 13-22	10.3	39
45	Idiosyncratic reaction after oxaliplatin infusion. <i>Annals of Oncology</i> , <b>2001</b> , 12, 132-3	10.3	42
44	Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). <i>Annals of Oncology</i> , <b>2000</b> , 11, 837-43	10.3	285
43	A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>Annals of Oncology</i> , <b>2000</b> , 11, 1309-11	10.3	29
42	The Value of Oxaliplatin in Combination with Continuous infusion □ Bolus 5-Fluorouracil and Levo-Folinic Acid in Metastatic Colorectal Cancer Progressing after 5FU-Based Chemotherapy: A Giscad (Italian Group for the Study of Digestive Tract) Cancer Phase II Trial. <i>Tumori</i> , <b>2000</b> , 86, 465-469	1.7	9
41	Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>British Journal of Cancer</i> , <b>1999</b> , 79, 491-4	8.7	6
40	A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>British Journal of Cancer</i> , <b>1999</b> , 80, 1595-8	8.7	72

39	A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. <i>Journal of Pain and Symptom Management</i> , <b>1999</b> , 17, 231-9	4.8	323
38	Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. <i>Journal of Pain and Symptom Management</i> , <b>1999</b> , 17, 240-7	4.8	303
37	Patients' opinions, feelings, and attitudes after a campaign to promote the Di Bella therapy. <i>Lancet, The</i> , <b>1999</b> , 353, 1310-4	4.0	26
36	A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>1999</b> , 10, 985-7	10.3	4
35	Which 5-fluorouracil regimen?--the great debate. <i>Anti-Cancer Drugs</i> , <b>1999</b> , 10, 337-54	2.4	15
34	Subcutaneous administration of interleukin-2 and interferon-alpha 2b in advanced renal cell carcinoma: long-term results. <i>Cancer Detection and Prevention</i> , <b>1999</b> , 23, 172-6		7
33	GIVIO-SITAC 01: A randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma--long term results and evaluation of the indicators of health-related quality of life. Gruppo Italiano Valutazione Interventi in Oncologia. Studio Italiano Terapia Adjuvante Colon. <i>Cancer</i> , <b>1998</b> , 83, 2135-44	6.4	47
32	Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia, and the Japanese Foundation for Cancer Research. <i>Lancet, The</i> , <b>1998</b> , 351, 1677-81	4.0	68
31	Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. <i>Lancet, The</i> , <b>1998</b> , 352, 1407-12	4.0	845
30	Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. <i>Annals of Oncology</i> , <b>1998</b> , 9, 105-8	10.3	185
29	Do specialists do it better? The impact of specialization on the processes and outcomes of care for cancer patients. <i>Annals of Oncology</i> , <b>1998</b> , 9, 365-74	10.3	71
28	5-FLUOROURACILE E TUMORI DEL COLON-RETTO: IMPIEGO NELLA PRATICA CLINICA E PROGETTO MISURA. <i>Tumori</i> , <b>1998</b> , 84, S10-S12	1.7	
27	Evaluation of Clinical Efficacy of New Medical Treatments in Advanced Colorectal Cancer. Results of a Workshop Organized by the Eortc Gitccg. <i>Tumori</i> , <b>1998</b> , 84, 335-347	1.7	11
26	Treatment of colorectal cancer. Current guidelines and future prospects for drug therapy. <i>Drugs</i> , <b>1997</b> , 53, 593-607	12.1	43
25	Should patients with advanced colorectal cancer be treated with chemothreapy?. <i>European Journal of Cancer</i> , <b>1997</b> , 33, 818-822	7.5	3
24	Should patients with advanced colorectal cancer be treated with chemotherapy?. <i>European Journal of Cancer</i> , <b>1997</b> , 33, 815-24	7.5	5
23	Gastrointestinal Tract Cancer Liaison Office: an attempt to organise clinical research in Europe. <i>European Journal of Cancer</i> , <b>1997</b> , 33, 1536-45	7.5	2
22	High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a 'GISCAD' phase III study. Italian Group for the Study of Digestive Tract Cancer. <i>Annals of Oncology</i> , <b>1997</b> , 8, 169-74	10.3	16

21	Response Evaluation as the Key-point in Results Interpretation. <i>Tumori</i> , <b>1997</b> , 83, 73-76	1.7	1
20	Biological indices predictive of survival in 519 Italian terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. <i>Journal of Pain and Symptom Management</i> , <b>1997</b> , 13, 1-9	4.8	93
19	Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study. <i>Supportive Care in Cancer</i> , <b>1997</b> , 5, 314-7	3.9	27
18	Cisplatin-associated anaemia in patients with solid tumours. A retrospective evaluation and considerations relative to erythropoietin administration. <i>Supportive Care in Cancer</i> , <b>1996</b> , 4, 218-9	3.9	5
17	Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study. <i>British Journal of Cancer</i> , <b>1995</b> , 72, 1531-5	8.7	22
16	Prognostic factors in resectable gastric cancer: results of EORTC study no. 40813 on FAM adjuvant chemotherapy. <i>Annals of Surgical Oncology</i> , <b>1995</b> , 2, 495-501	3.1	23
15	Oral etoposide as second-line chemotherapy for colorectal cancer: a GISCAD study. Gruppo Italiano Studio Carcinomi Apparato Digerente. <i>Journal of Chemotherapy</i> , <b>1995</b> , 7, 246-8	2.3	5
14	Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report. <i>Cancer</i> , <b>1995</b> , 76, 1694-9	6.4	45
13	Mediterranean Kaposi's sarcoma in the elderly. A randomized study of oral etoposide versus vinblastine. <i>Cancer</i> , <b>1994</b> , 74, 2873-8	6.4	46
12	Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon-alpha 2b and folinic acid. The "GISCAD" experience. Italian Group for the Study of Digestive Tract Cancer. <i>European Journal of Cancer</i> , <b>1994</b> , 30A, 1611-6	7.5	6
11	Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma. <i>European Journal of Cancer</i> , <b>1994</b> , 30A, 338-43	7.5	21
10	A cisplatin-cyclophosphamide regimen in advanced ovarian cancer: reporting 5-year results. <i>Oncology</i> , <b>1993</b> , 50, 92-9	3.6	2
9	Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. <i>Cancer</i> , <b>1993</b> , 72, 3099-105	6.4	107
8	Chemotherapy for patients not benefitting from 5-fluorouracil therapy. <i>Journal of Surgical Oncology</i> , <b>1991</b> , 2, 161-4	2.8	
7	Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study. <i>European Journal of Cancer &amp; Clinical Oncology</i> , <b>1988</b> , 24, 1579-81		17
6	Epirubicin treatment of advanced breast carcinoma with the weekly low-dose regimen. <i>Oncology</i> , <b>1987</b> , 44, 6-12	3.6	17
5	The meaning of bites on the vectorcardiogram: study in adriamycin cardiomyopathy. <i>Journal of Electrocardiology</i> , <b>1982</b> , 15, 265-70	1.4	9
4	Cardiac Toxicity of 5-Fluorouracil: A Study on 1083 Patients. <i>Tumori</i> , <b>1982</b> , 68, 505-510	1.7	201



3	Antitumor chemotherapy after fluorouracil angina. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>1982</b> , 104, 321-2	4.9	12
2	Cardiac toxicity from antitumor therapy. <i>Oncology</i> , <b>1980</b> , 37 Suppl 1, 51-8	3.6	20
1	Carcinoembryonic antigen revisited. <i>Lancet, The</i> , <b>1977</b> , 1, 756	40	